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sents the only chance to improve survival and quality of life in
these rare cases.
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Mechanical aortic valve malfunction: An intraoperative BioGlue
complication
Mohsen Karimi, MD,a Richard E. Kerber, MD,b and Jeffrey E. Everett, MD,a Iowa City, Iowa
We report a case of intraoperative mechanical aorticvalve malfunction after application of BioGlue(Cryolife, Inc, Kennesaw, Ga) over the aortotomyclosure.
Clinical Summary
A 62-year-old woman, weighing 48 kg, with symptomatic com-
bined aortic stenosis and insufficiency presented for elective valve
replacement.
After median sternotomy, the aorta was cannulated, and a
single dual-stage venous cannula was placed through the right
atrial appendage. Antegrade and retrograde cold blood cardiople-
gia with moderate core hypothermia (32°C) constituted the car-
dioprotective strategy. The left ventricle was vented through the
right superior pulmonary vein. Exposure of the aortic valve was
obtained through a transverse aortotomy. The valve was severely
calcified. The valve was excised in its entirety and calcium debrided.
The patient’s native root was small, and the annulus size was 19 mm.
A 19-mm St Jude Regent Mechanical valve (St Jude Medical, Inc, St
Paul, Minn) was chosen because it would provide acceptable hemo-
dynamics. The valve was seated into position successfully, and each
of the leaflets moved freely. The aortotomy was next closed in 2
layers with 4-0 Prolene suture (Ethicon, Inc, Somerville, NJ). The
suture line was checked for integrity with administration of cardio-
plegia in antegrade fashion. The closure appeared hemostatic with the
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Figure 1. Aortic insufficiency after BioGlue (Cryolife, Inc, Kenne-
saw, Ga) application.
Figure 2. Restoration of valve function after removal of BioGlue.
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exception of bleeding through the suture holes. Therefore, the suture
line was reinforced with BioGlue. After the patient was separated
from cardiopulmonary bypass, the function of the valve was deter-
mined through intraoperative transesophageal echocardiography.
There appeared to be a significant amount of aortic insufficiency
(Figure 1). The crossclamp was reapplied, additional cardioplegia was
given, and the suture lines were taken down. Inspection of the valve
revealed that BioGlue had migrated through the suture line and
impinged on 1 of the 2 leaflets. We were able to remove the glue, free
the leaflet, and restore the functional hinge mechanism. The aorto-
tomy was subsequently closed in 2 layers with 4-0 Prolene and no
BioGlue reinforcement. The patient was separated from cardiopulmo-
nary bypass with a functional valve confirmed by intraoperative
transesophageal echocardiography (Figure 2).
Discussion
BioGlue is a preparation of bovine albumin cross-linked with
glutaraldehyde to form a strong adhesive bond. It is supplied in a
2-barrel applicator containing albumin in 1 barrel and glutaralde-
hyde in 1 barrel, which are mixed at the time of application. After
mixture, the glue solidifies in approximately 30 seconds and
achieves maximum strength in approximately 2 to 3 minutes.1 The
use of BioGlue in aortic surgery was met with great enthusiasm,
because it not only increased the strength of the friable aortic walls
in aortic dissection when it was applied between the dissected
aortic layers but also proved effective as a sealing agent at the
anastomotic suture line.2
Some experimental and clinical studies have reported the effect
of BioGlue in creating local tissue damage and local inflammatory
response, and increasing risk of pseudoaneurysm formation and
great vessel stenosis especially in the pediatric population.3 Ex-
perimental studies in piglets have shown vascular growth impair-
ment and anastomotic stricture as the result of circumferential
application of BioGlue around aortic anastomosis.4 Recently, there
was a case report of superior vena cava stenosis as the result of an
inappropriately large amount of BioGlue placed between the roof
of the left atrium, the superior vena cava, and the aortic root for
persistent bleeding.5 In our case, the liquid glue seeped through the
2-layer aortotomy closure and fused the mechanical valve leaflet as
a result of delayed solidification.
We believe that BioGlue is a useful adjunct in achieving a
hemostatic aortic anastomosis and reapproximating the dissected
aortic wall layers. However, it should be sparingly and cautiously
used during mechanical valve surgery with the fear of leakage of
some unsolidified glue into the valve apparatus and associated
malfunctioning of the leaflets.
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